Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma.

@article{Khan2004ClinicalUO,
  title={Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma.},
  author={Nayela Khan and Charles J Cromer and Michael Campa and Edward F. Patz},
  journal={Cancer},
  year={2004},
  volume={101 2},
  pages={379-84}
}
BACKGROUND Early lung carcinoma detection strategies involving imaging studies have yet to demonstrate a reduction in mortality. Identification of serum biomarkers that could complement radiologic studies and facilitate earlier diagnosis of lung carcinoma would be of significant benefit to patients. In the current pilot study, the authors evaluated two overexpressed proteins in lung carcinoma, serum amyloid A (SAA) and macrophage migration inhibitory factor (MIF), as potential diagnostic serum… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Serum amyloid A is a novel prognostic biomarker in hepatocellular carcinoma.

Asian Pacific journal of cancer prevention : APJCP • 2014
View 2 Excerpts

Similar Papers

Loading similar papers…